Aprepitant: 6 agencies, 2004–2026
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
On the same population the two systems disagree outright: AWMSG (Wales) recorded recommended for “Prevention of nausea and vomiting associated with highly and moderately emetogenic cancer chemotherapy in patients from …”, while SMC (Scotland) recorded not recommended for “Prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy”.
The file has been open for more than a decade: 21.2 years separate the first record, 8 Nov 2004 at SMC (Scotland), from the most recent, 12 Feb 2026 at PHARMAC (New Zealand).
SMC (Scotland) changed its position: restricted on 8 Nov 2004, recommended by 10 Jul 2017.
No assessment is on file from CIPM (Spain) and G-BA (Germany), each among the eight highest-volume agencies here.
The file is active: 3 of 20 records date from 2023 or later.
6 distinct indication wordings are recorded for aprepitant by the agencies that label one in English (AWMSG, PBAC and SMC).
3 of these 20 records carry a year of decision but no day, so any interval quoted here is approximate to within a year.
SMC (Scotland) was first to assess aprepitant, on 8 Nov 2004; AWMSG (Wales) did not open a file until 27 Jul 2016 — an unusually long tail of 11.7 years between the earliest and latest system to look at it.
The record arrives in waves: 5 separate years each carry two or more decisions, spread across 10 years in total.
4 of the 6 agencies here assessed aprepitant more than once, HAS (France) most often at 6 entries — repeat review is the norm for this molecule rather than the exception.
6 of the 18 agencies in this archive hold a record for aprepitant.
The full ledger for aprepitant reads 13 recommended, 3 other, 2 not recommended and 1 advice, with 1 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| PHARMAC (New Zealand) | 30 Aug 2023 | Nausea and vomiting associated with moderately emetogenic chemotherapy | PTAC advice: No Formal Recommendation · decision reached | source |
| PBAC (Australia) | 2019 | Nausea and vomiting | The PBAC recommended a Section 100 (Efficient Funding of Chemotherapy – Related Benefits) … | source |
| HAS (France) | 17 Apr 2019 | Listing (Transparency Committee) | SMR substantial · ASMR V | source |
| AWMSG (Wales) | 27 Jul 2016 | Prevention of nausea and vomiting associated with highly and moderately emetogenic cancer chemotherapy in patients from … | recommended (limited) | source |
| SMC (Scotland) | 7 Nov 2011 | As part of combination therapy, for prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy. | not recommended | source |
15 further decisions for aprepitant, across 5 agencies, are not shown here. They include the most recent record on file, 12 Feb 2026 from PHARMAC (New Zealand); its outcome is in the subscriber dataset. They link to 12 further source documents.
Related molecules
- ondansetron — same ATC class A04A — Antiemetics
- netupitant / palonosetron — same ATC class A04A — Antiemetics
- palonosetron — same ATC class A04A — Antiemetics
- granisetron — same ATC class A04A — Antiemetics
- fosaprepitant — same ATC class A04A — Antiemetics
- infliximab — also decided by PHARMAC in 2026Q1
Coverage: 20 decisions for aprepitant from 6 agencies, 2004 to 2026. Data to 7 Sep 2026. ATC class A04A — Antiemetics. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.